Organon & Co.

11/10/2025 | Press release | Distributed by Public on 11/10/2025 05:13

Amendment to Quarterly Report (Form 10-Q/A)

3
PART I FINANCIAL INFORMATION 5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 5
Item 4. Controls and Procedures 16
PART II OTHER INFORMATION 19
Item 6. Exhibits 19
Signatures 20

The following notations in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as amended, have the meanings as set forth below:

"1" Indicates, in this Quarterly Report on Form 10-Q, as amended, brand names of products, that are not available in the United States.

"2" Indicates, in this Quarterly Report on Form 10-Q, as amended, brand names of products that are trademarks not owned by Organon & Co. or its subsidiaries. Actemra is a trademark registered in the United States in the name of Chugai Seiyaku KK.; Humira is a trademark registered in the United States in the name of AbbVie Biotechnology Ltd.; Enbrel is a trademark registered in the United States in the name of Immunex Corporation; Remicade is a trademark registered in the United States in the name of Janssen Biotech, Inc.; Herceptin and Perjeta are trademarks registered in the United States in the name of Genentech, Inc.; Emgality is a trademark registered in the United States in the name of Eli Lilly and Company (used under license); and Rayvow is a registered trademark of Eli Lilly in the European Union and other countries (used under license). Brand names of products that are in all italicized letters, without the footnote, are trademarks of, or are otherwise licensed by, Organon & Co. and/or one of its subsidiaries.

Organon & Co. published this content on November 10, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 10, 2025 at 11:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]